7:30 am
Registration & Welcome Coffee

8:30 am Chair’s Opening Remarks

  • Shaker Mousa Professor & Chairman, Founder & Executive Vice President, Albany College, NanoPharmaceuticals

8:40 am Agonist Mechanisms to Address the Treatment Paradigm


  • Most integrin-targeted candidates use antagonist mechanisms
  • Explore the potential of positive regulation on integrins
  • Assess the benefits of this compared to antagonists

Structural Biology & Medicinal Chemistry for Drug Development

9:10 am Targeting Integrin Signaling


  • Evaluate this novel approach to specific targeting of integrin signaling
  • Avoid downstream cascades by blocking on specific signals
  • Define the potential of this method to avoid off-target immune response

9:40 am Panel Discussion: Genesis of 7 Hills Pharma & Translation of Integrin Agonist into the Clinic


  • Translating Biology into Clinic – potential clinical indications (augmenting infectious disease vaccination and solid tumor immunity)
  • Why have there been limited development of integrin agonists? Safety and efficacy?
  • The game changer? What data gives us the confidence of this approach?

10:15 am
Speed Networking & Morning Break


This session is the ideal opportunity to network and forge meaningful business relationships with many of the brightest minds working in the Integrin field, face to-face for the first time

11:00 am Utilizing Vascular Integrins as a Therapeutic Target for Acute & Long-COVID


  • Vascular integrins including alpha5beta1 and alphavbeta3 are experimentally validated receptors for SARS-CoV-2
  • Acute blockade of these integrins with clinically validated inhibitors can reduce SARS-CoV-2 infection
  • Chronic blockade of these integrins may also be therapeutic in cerebrovascular manifestations of long-COVID

11:30 am New Structural Insights into the Basis of Integrin-Ligand Interactions


  • Structure-based analysis of integrin function using single particle cryoelectron microscopy (Cryo-EM)
  • Structural dynamics of ligand-receptor interactions
  • Using cryo-EM for therapeutic antibody development

12:00 pm Roundtable Discussion:Specific v Pan Inhibition of Integrins


  • Integrin targets are very widely expressed
  • Define specificity early on to ensure off-target effects are minimized down-stream
  • Assess the advantages and disadvantages of specific versus pan inhibition of integrins
  • Discuss with your peers in this roundtable discussion, grouped by disease indication
  • Down stream adaptor proteins

1:00 pm
Lunch Break

Preclinical Development in Intergrin Binding & Targeting

2:00 pm Targeting Integrins in the Tumor Microenvironment


  • Explore the role of integrins in the tumor, including tumorigenesis
  • Translate this understanding into innovative therapeutic mechanisms
  • Case study – review this in preclinical models to assess to benefits of these mechanisms

2:30 pm Development of OTT166 an RGD-Binding Integrin Antagonist for the Topical Treatment of Diabetic Retinopathy


  • Distributes to posterior segment of the eye after eye drop administration
  • Reduces neovascularization and vessel leakage in multiple animal models of diabetic retinopathy and wet-AMD
  • Phase 1 clinical data show safety and tolerability and evidence of biological activity – proceeding to Phase 2

3:00 pm
Afternoon Break

3:30 pm Fixing the Failures of Classic Alpha V Beta 3 Inhibitors

  • Shaker Mousa Professor & Chairman, Founder & Executive Vice President, Albany College, NanoPharmaceuticals


  • Consider the lessons learned from previous clinical failures in a preclinical setting
  • Pinpoint the problems with these in order to re-assess the MoAs
  • Overcome these challenges to design novel therapeutics

4:00 pm Panel Discussion:

  • Eric Lefevbre Chief Medical Officer, Pliant Therapeutics
  • Scott Edwards Chief Development Officer, OcuTerra
  • Shaker Mousa Professor & Chairman, Founder & Executive Vice President, Albany College, NanoPharmaceuticals


Finish up your Conference Day One day with an open discussion with our expert speakers to ensure all your
questions are answered, including:

  • The binding of integrins
  • The role of integrins in autoimmune diseases, opthalmic disorders and more

4:30 pm
End of Conference Day One

4:45 pm
Poster Networking Session


Use this break to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships, whilst exploring the latest scientific posters within the integrin space